Beth Overmoyer
Publications by Year
Research Areas
Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research, Cancer Treatment and Pharmacology, Advanced Breast Cancer Therapies, Cancer Immunotherapy and Biomarkers
Most-Cited Works
- → Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer(2005)1,307 cited
- → Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer(2015)735 cited
- → Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas(2005)622 cited
- → Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer(2005)547 cited
- A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer.(2002)
- → Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies(2005)364 cited
- → Trastuzumab and Vinorelbine as First-Line Therapy for HER2-Overexpressing Metastatic Breast Cancer: Multicenter Phase II Trial With Clinical Outcomes, Analysis of Serum Tumor Markers as Predictive Factors, and Cardiac Surveillance Algorithm(2003)345 cited
- → Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer(2019)277 cited
- → The influence of young age on outcome in early stage breast cancer(1994)242 cited
- → A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer.(2010)151 cited